Please login to the form below

Not currently logged in
Email:
Password:

biomarkers

This page shows the latest biomarkers news and features for those working in and with pharma, biotech and healthcare.

Merck’s Bavencio joins first-line kidney cancer face-off

Merck’s Bavencio joins first-line kidney cancer face-off

There was a significant benefit regardless of whether the patients’tumours expressed the PD-L1 biomarker, with the ‘all-comer’group seeing a 31% reduction in PFS versus Sutent, and the

Latest news

More from news
Approximately 5 fully matching, plus 264 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest appointments

  • BMS appoints CCO, Stephen Davies joins Eisai and more BMS appoints CCO, Stephen Davies joins Eisai and more

    The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy.

  • Industry appointments Industry appointments

    Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma

  • Annalisa Jenkins joins biomarker firm PlaqueTec as CEO Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

    Annalisa Jenkins joins biomarker firm PlaqueTec as CEO. She arrives from US-based Dimension Therapeutics, where she was CEO. ... UK-based PlaqueTec has appointed Annalise Jenkins as its chief executive officer, a role that will see her lead the 2018

  • Paul Stockdale joins Oxford BioDynamics as CFO Paul Stockdale joins Oxford BioDynamics as CFO

    A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

  • Stephen Eck joins Aravive Biologics Stephen Eck joins Aravive Biologics

    Ray Tabibiazar, founding president and CEO of Aravive, said: “Stephen has an impressive track-record of oncology drug and biomarker development at prominent pharmaceutical companies, as well as a close relationship

More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest from PMHub

  • A4P Bio Consulting Ltd

    A4P Bio Consulting Ltd. As experts in biomarkers, bioanalysis, pharmacokinetics, logistics and quality systems management A4P deliver scientifically robust, regulatory compliant, cost effective and value added solutions for the global life

  • Is the pharma business model ready for precision medicine?

    It exists at the convergence of genomic sequencing, biomarker research, bioinformatics and big data analysis. ... This differs from traditional tumour type or ‘ adaptive’ trials where the predictive biomarker is not clearly identified at trial

  • Marketing strategy in complex environments

    Marketing strategy in complex environments. Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through

  • Case Study: Oncology diagnostic biomarker landscaping study

    Case Study: Oncology diagnostic biomarker landscaping study. The challenge:. Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. ... They wanted to understand the current market landscape,

  • Raising Awareness: It’s World COPD Day today!

    These imaging endpoints may be used as biomarkers of COPD that can be used to phenotype and treat patients’ accordingly (8).

More from PMHub
Approximately 4 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics